At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 272 enrolled
Drug / intervention
600 mg AZD7442 IV +1 moredrug
Likely dose
600 mg AZD7442 IVfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
In Brief
A Phase 2 clinical trial evaluating 600 mg AZD7442 IV and 600mg placebo IV for Coronavirus Disease 2019 (COVID-19). Completed, enrolled 272 participants across 14 sites.
Detailed Summary
To evaluate the safety and tolerability of a single dose of 600 mg AZD7442 administered IV (intravenous) to Chinese adults (including those with stable medical conditions).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 (COVID-19)
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionAug 2022
Study CompletionMay 2023
TodayJul 2026
First PostedJan 11, 2022
Enrollment StartDec 3, 2021
Primary CompletionAug 15, 2022
Study CompletionMay 6, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.5 years ago
Interventions
600 mg AZD7442 IVdrug
Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
600mg placebo IVdrug
Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.